Home › NDC Lookup › Ingredients › Mometasone Furoate › 70000-0635-02
Leader Allergy Nasal mometasone furoate 50 ug Spray, Metered — NDC 70000-0635-02 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Leader Allergy Nasal mometasone furoate 50 ug Spray, Metered — NDC 70000-0635-2 (Billing 70000-0635-02)

by Cardinal Health 110, LLC. dba Leader · 1 BOTTLE, SPRAY in 1 PACKAGE / 120 SPRAY in 1 BOTTLE, SPRAY

This is a package of Leader Allergy Nasal mometasone furoate 50 ug Spray, Metered from Cardinal Health 110, LLC. dba Leader, marketed since Sep 2023 and currently FDA-listed; retail pharmacies pay about $0.7141 per mL (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 70000-0635-02
🏷️ FDA NDC (as labeled) 70000-0635-2 billing pads the package segment with a zero
This package
Contains120 spray in 1 bottle, spray Cost per mL$0.7141 NADAC Pack sizes2 compare ↓
Also priced by: Medicaid pays $1.87/unit — full pricing hub ↓
Main listing for product 70000-0635 · Also comes in: 1 bottle 70000-0635-1
OTC Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 70000-0635-2 alone.

Record
FDA NDC Directory package listing · Human OTC drug
Code segments
70000 labeler · 0635 product · 2 package
Package marketed since
Sep 22, 2023
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 7000006352 8
Medicaid fills, this package
44 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026
⚠️
Other active recalls for Mometasone Furoate (different manufacturers) — 2 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class III · May 28, 2024 — Defective Container (Organon Llc) · FDA recall D-0551-2024
Class III · May 28, 2024 — Defective Container (Organon Llc) · FDA recall D-0550-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 70000-0635-2
Product NDC 70000-0635
11-digit billing NDC 70000063502
NCPDP billing unit ML — per mL (volume)
RxCUI 1797865
UNII MTW0WEG809
Application # NDA215712
SPL Set ID 26f929e8-0759-4584-a0bf-f7709baa6bee
Established class (EPC) Corticosteroid
Mechanism of action Corticosteroid Hormone Receptor Agonists
DEA schedule Non-controlled
Marketing category NDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2023-09-22
Route NASAL
Dosage form SPRAY, METERED
Substance MOMETASONE FUROATE MONOHYDRATE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 083194
GCN 52083
HICL code 003329
Ingredient (HICL) Mometasone Furoate
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q7
Therapeutic class — intermediate (HIC2) Nasal Preparations
HIC3 code Q7P
Therapeutic class — specific (HIC3) Nasal Anti-Inflammatory Steroids
AHFS code 52:08.08.00
AHFS class Corticosteroids (Eent)
FDB label name ALLERGY NASAL 50 MCG SPRAY
FDB brand name Allergy Nasal
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 083194
  • GCN: 52083
  • HICL (First Databank): 003329
  • AHFS class code: 52:08.08.00
  • RxCUI (RxNorm): 1797865
Why two NDCs? The FDA registers this code as 70000-0635-2 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 70000-0635-02. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Corticosteroid class.

Pharmacologic class Corticosteroid
Drug family (ATC) Corticosteroids, potent (group III), Corticosteroids, Glucocorticoids
How it works Corticosteroid Hormone Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name ALLERGY NASAL 50 MCG SPRAY Ingredient Mometasone Furoate
📖 What it is MedlinePlus · NLM

Mometasone nasal spray is used to prevent and relieve symptoms of sneezing, runny, stuffy, or itchy nose caused by hay fever or other allergies. It is also used to treat nasal polyps (swelling of the lining of the nose). Mometasone nasal spray should not be used to treat symptoms (e.g., sneezing, stuffy, runny, itchy nose) caused by the common cold. Mometasone nasal spray is in a class of medications called corticosteroids. It works by blocking the release of certain natural substances that cause allergy symptoms.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It depends on the product. The nasal spray treats hay fever symptoms and nasal polyps, Asmanex inhalers treat asthma long term, Sinuva treats nasal polyps after sinus surgery, and...
  • No. Asmanex is for daily control, not quick relief. Use your fast-acting rescue inhaler, and call your doctor if your asthma isn't responding.
  • Can I use my Asmanex inhaler during an asthma attack?
  • Inhaled steroids can cause thrush, a yeast infection in the mouth and throat. Rinse with water and spit it out, without swallowing, after every dose.
📖 Read our full Mometasone guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.714 —
Medicaid paysCMS SDUD · 12 mo $1.87 —
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per mL) — tap or hover for the price & month
Dec 2025 Mar 2026 Jun 2026 Sep 2026 $0.714 $0.637
▲ Up 5% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
70000-0635-01 70000-0635-1 1 BOTTLE, SPRAY in 1 PACKAGE / 60 SPRAY in 1 BOTTLE, SPRAY — — 2023-09-22 — Active
70000-0635-02 You're viewing this Main listing 1 BOTTLE, SPRAY in 1 PACKAGE / 120 SPRAY in 1 BOTTLE, SPRAY $0.7141 / mL — 2023-09-22 — Active

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 1 bottle, spray in 1 package / 120 spray in 1 bottle, spray.
What NDC number is used to bill for this package of Leader Allergy Nasal mometasone furoate 50 ug Spray, Metered?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Leader Allergy Nasal 50 ugthis 70000-0635-02 Cardinal 1 bottle $0.714 — Availability likely —
Nasonex 50 ug 00113-1720-02 L. 1 bottle $1.193 — Availability likely +67%
Mometasone Furoate Monohydrate 50 ug 59651-0402-17 Aurobindo 1 bottle $1.587 AB Availability likely +122%
Mometasone Furoate 50 ug 60505-0830-01 Apotex 1 bottle $1.587 AB Availability likely +122%
Mometasone Furoate 50 ug 65162-0891-29 Amneal 1 bottle $1.587 AB Discontinued +122%
Childrens Nasonex 50 ug 00113-1999-01 L. 1 bottle — — FDA listed —
allergy nasal 50 ug 00363-2060-02 Walgreen 1 bottle — — FDA listed —
Rugby mometasone furoate nasal 50 ug 00536-1381-30 Rugby 1 bottle — — FDA listed —
Allergy 50 ug 11822-7099-00 Rite 1 bottle — — Discontinued —
allergy 50 ug 42507-0182-02 HyVee 1 bottle — — FDA listed —
allergy 50 ug 51316-0117-11 CVS 1 bottle — — FDA listed —
Allergy Relief 50 ug 51316-0172-11 CVS 1 bottle — — FDA listed —
Mometasone Furoate 50 ug 58602-0522-44 Aurohealth 1 bottle — — FDA listed —
Mometasone Furoate 50 ug 60429-0664-17 Golden 1 bottle — AB FDA listed —
basic care allergy 50 ug 72288-0610-02 Amazon.com 1 bottle — — FDA listed —
topcare allergy 50 ug 76162-0134-02 Topco 1 bottle — — FDA listed —
Allergy 50 ug 72288-0506-02 Amazon.com 1 bottle — — FDA listed —
About this product: this is the brand-name version. FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2023
On the market since
Sep 2023
📍
2026
Currently FDA-listed
3 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Mometasone inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerCardinal Health 110, LLC. dba Leader
Application holderPERRIGO PHARMA INTERNATIONAL DAC
FDA applicationNDA215712 (NDA)
Labeler code70000
First marketedSep 2023
Product typeHuman Otc Drug
Portfolio163 products on file

More NDCs from Cardinal Health 110, LLC. dba Leader labeler code 70000

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 📦 Storage and Handling 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Do Not Use 📄 Ask a Doctor Before Use If 📄 Ask a Doctor or Pharmacist Before Use If 📄 When Using This Product 📄 Stop Use and Ask a Doctor If 🤰 If Pregnant or Breast-Feeding 📄 Keep Out of Reach of Children 📄 Questions or Comments 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 24 words ▾

Uses temporarily relieves these symptoms of hay fever or other upper respiratory allergies: • nasal congestion • runny nose • sneezing • itchy nose

⏱️ Dosage and Administration 143 words ▾

Directions Read insert (inside package) for how to: • prime the bottle • use the spray • clean the nozzle • shake well before each use • use this product only once a day • do not use more than directed Adults & children 12 years of age and older • 2 sprays in each nostril once daily while sniffing gently Children 2 to 11 years of age • the growth rate of some children may be slower while using this product. Children should use for the shortest amount of time necessary to achieve symptom relief. Talk to your child’s doctor if your child needs to use the spray for longer than two months a year. • an adult should supervise use • 1 spray in each nostril once daily while sniffing gently Children under 2 years of age • do not use

⚠️ Warnings ~2 min read ▾

Warnings Only for use in the nose. Do not spray into your eyes or mouth. Do not use • in children under 2 years of age • to treat asthma • if you have an injury or surgery to your nose that is not fully healed • if you have ever had an allergic reaction to this product or any of the ingredients Ask a doctor before use if you • have an eye infection • have or had glaucoma or cataracts Ask a doctor or pharmacist before use if you are taking • medicine for HIV infection (such as ritonavir) • a steroid medicine for asthma, allergies or skin rash • ketoconazole pills (medicine for fungal infection) When using this product • the growth rate of some children may be slower • stinging may occur for a few seconds right after use • you may start to feel relief within 12 hours and full effect after several days of regular, once-a-day use • do not share this bottle with anyone else as this may spread germs • remember to tell your doctor about all the medicines you take, including this one Stop use and ask a doctor if • you have, or come into contact with someone who has chickenpox, measles or tuberculosis • your symptoms do not get better within 7 days of starting use or you get a new symptom such as severe facial pain or thick nasal discharge.

You may have something more than allergies, such as an infection. • you get a constant whistling sound from your nose. This may be a sign of damage inside your nose. • you get an allergic reaction to this product. Seek medical help right away. • you get new changes to your vision that develop after starting this product • you have severe or frequent nosebleeds If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).

📦 Storage and Handling 41 words ▾

Other information • do not use if tape printed with “sealed for your protection” on top and bottom carton flaps is not intact • keep package and insert. They contain important information. • store between 20-25 ° C (68-77 ° F)

🧪 Active Ingredient 11 words ▾

Active ingredient (in each spray) Mometasone furoate monohydrate (glucocorticoid) 50 mcg

🧪 Inactive Ingredients 18 words ▾

Inactive ingredients benzalkonium chloride, citric acid, glycerin, microcrystalline cellulose and carboxymethylcellulose sodium, polysorbate 80, purified water, sodium citrate

🎯 Purpose 4 words ▾

Purpose Allergy symptom reliever

📄 Do Not Use 48 words ▾

Do not use • in children under 2 years of age • to treat asthma • if you have an injury or surgery to your nose that is not fully healed • if you have ever had an allergic reaction to this product or any of the ingredients

📄 Ask a Doctor Before Use If 19 words ▾

Ask a doctor before use if you • have an eye infection • have or had glaucoma or cataracts

📄 Ask a Doctor or Pharmacist Before Use If 36 words ▾

Ask a doctor or pharmacist before use if you are taking • medicine for HIV infection (such as ritonavir) • a steroid medicine for asthma, allergies or skin rash • ketoconazole pills (medicine for fungal infection)

📄 When Using This Product 74 words ▾

When using this product • the growth rate of some children may be slower • stinging may occur for a few seconds right after use • you may start to feel relief within 12 hours and full effect after several days of regular, once-a-day use • do not share this bottle with anyone else as this may spread germs • remember to tell your doctor about all the medicines you take, including this one

📄 Stop Use and Ask a Doctor If 116 words ▾

Stop use and ask a doctor if • you have, or come into contact with someone who has chickenpox, measles or tuberculosis • your symptoms do not get better within 7 days of starting use or you get a new symptom such as severe facial pain or thick nasal discharge. You may have something more than allergies, such as an infection. • you get a constant whistling sound from your nose. This may be a sign of damage inside your nose. • you get an allergic reaction to this product.

Seek medical help right away. • you get new changes to your vision that develop after starting this product • you have severe or frequent nosebleeds

🤰 If Pregnant or Breast-Feeding 10 words ▾

If pregnant or breast-feeding, ask a health professional before use.

📄 Keep Out of Reach of Children 22 words ▾

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).

📄 Questions or Comments 6 words ▾

Questions or comments? Call toll-free 1-800-719-9260

📄 Package Label / Principal Display Panel 69 words ▾

Package/Label Principal Display Panel LEADER ™ Non-Drowsy | Scent-Free Mist Allergy Nasal Spray Mometasone Furoate Nasal Spray, 50 mcg/Spray Allergy Symptom Reliever (Glucocorticoid)* Allergy + Congestion Full Prescription Strength 24-Hour Relief of: Nasal Congestion Runny Nose Sneezing Itchy Nose COMPARE TO NASONEX ® 24HR ALLERGY active ingredient 100% Money Back Guarantee *Mometasone furoate is a steroid medicine known as a glucocorticoid 60 SPRAYS

0.34FL OZ (10.0 mL) leader-allergy-nasal-spray-carton-image.jpg

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
44
Units reimbursed last 4 qtrs
748
Gross reimbursed last 4 qtrs
$1.4K
Avg / prescription
$31.81
Avg / unit
$1.8710
Latest quarter Q1 2026
18Rx
Medicaid pays / mL
$1.8710
gross reimbursed
vs
NADAC / mL
$0.7141
acquisition cost
=
Spread
+$1.1569
+162% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
100% FFS
Fee-for-service · 44 Rx Managed care · 0 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 748 units · 3.8 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: no data reported OH Pennsylvania: no data reported PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: no data reported CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
3.83.8
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New York 3.8 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 bottle this page70000-0635-02 44 Rx · $1,399
1 bottle70000-0635-01 No Medicaid data
Drug total (last 4 qtrs): 44 Rx · 748 units · $1,399 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Mometasone Furoate (matched by generic name) — the program that covers self-administered drugs. 9 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Mometasone Furoate. CMS lists 3 products for this generic; we show the highest-spend one. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$8.35M
Claims incl. refills
244.2K
Beneficiaries
188.1K
Spend / beneficiary
$44.41
Spend / claim
$34.22
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Leader Allergy Nasal (this brand).

Top reported reactions

Dyspnoea962
Asthma876
Headache874
Cough725
Fatigue666
Pruritus609
Gastrooesophageal Reflux Disease580

Age at onset

Neonate13
Infant11
Child185
Adolescent132
Adult1,331
Elderly777

Reporter sex

10,030 reports
Male · 38%
Female · 62%
Unknown · 0%

Serious outcomes

Hospitalization3,090
Death476
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 1,211 507
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
← 70000-0633-01 · LEADER/ 70000-0636-01 · Cardinal →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.